Skip to content
HowShorted

Karyopharm Therapeutics Inc. short interest in 2019

In 2019, Karyopharm Therapeutics Inc.'s disclosed short interest ran from 9.96% of shares outstanding on 15 Jan 2019 to 15.24% on 31 Dec 2019, a change of +5.28 percentage points. The year's high was 23.68% on 13 Sep 2019 and its low 9.83% on 31 Jan 2019, averaging 15.40% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.27 days on 15 Jan 2019. Full history: Karyopharm Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Karyopharm Therapeutics Inc. in 2019

2019 in figures

Start of year
9.96% (15 Jan 2019)
End of year
15.24% (31 Dec 2019)
Change
+5.28 pp
High
23.68% (13 Sep 2019)
Low
9.83% (31 Jan 2019)
Average
15.40%
Highest days to cover
12.27 (15 Jan 2019)
SEC filings marked
8

Every report in 2019

Karyopharm Therapeutics Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20199.96%12.27
31 Jan 20199.83%9.49
15 Feb 201912.55%5.82
28 Feb 201912.92%1.6710-K filed, results (8-K)
15 Mar 201912.55%3.04
29 Mar 201912.33%5.31
15 Apr 201912.45%11.42
30 Apr 201911.59%12.21
15 May 201910.97%11.4510-Q filed, results (8-K)
31 May 201913.20%4.59
14 Jun 201914.72%9.40
28 Jun 201914.39%7.73
15 Jul 201916.55%1.23
31 Jul 201918.49%6.12
15 Aug 201918.31%7.78results (8-K), 10-Q filed
30 Aug 201919.02%9.89
13 Sep 201923.68%8.27
30 Sep 201923.07%6.60
15 Oct 201919.49%7.34
31 Oct 201917.02%10.67
15 Nov 201917.32%5.5910-Q filed, results (8-K)
29 Nov 201917.68%11.52
13 Dec 201916.35%7.66
31 Dec 201915.24%8.39

See also: Karyopharm Therapeutics Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.